ArticleJournal of neuro-oncology2005
Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index.
Article in Journal of neuro-oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers.Clinical neuropathologyGuideline
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.Cancer immunology, immunotherapy : CII · 2016Trial
- Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- The role of the Ki-67 labelling index as an independent prognostic factor in indonesian glioma patients.Histology and histopathology · 2025Article
- A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma.Scientific reports · 2024Article
- Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.Cancers · 2024Review
- Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma.Cell communication and signaling : CCS · 2023Review
- The Comparative Experimental Study of Sodium and Magnesium Dichloroacetate Effects on Pediatric PBT24 and SF8628 Cell Glioblastoma Tumors Using a Chicken Embryo Chorioallantoic Membrane Model and on Cells In Vitro.International journal of molecular sciences · 2022Article
- OSlgg: An Online Prognostic Biomarker Analysis Tool for Low-Grade Glioma.Frontiers in oncology · 2020Article
- An Autophagy-Related Gene Signature Associated With Clinical Prognosis and Immune Microenvironment in Gliomas.Frontiers in oncology · 2020Article
- Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor GrowthClinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination.Oncotarget · 2017Article
- Functional analysis of KIF20A, a potential immunotherapeutic target for glioma.Journal of neuro-oncology · 2017Article
- Survivin and gliomas: A literature review.Oncology letters · 2016Article
- Expression of estrogen and progesterone receptors in astrocytomas: a literature review.Clinics (Sao Paulo, Brazil) · 2016Review
- A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors.Scientific reports · 2015Article
- Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma.Disease markers · 2015Article
- Article
- Ependymomas: development of immunotherapeutic strategies.Expert review of neurotherapeutics · 2013Review
- Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition.Journal of neuro-oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSurvivin has been identified as a protein expressed in cancer cells and a member of the inhibitor-of-apoptosis protein family. Recent studies suggest that the expression of survivin increases during the G2/M phase of the cell cycle, and may be used in clinical prognosis. We examined whether survivin expression in human gliomas would be a correlative of prognosis.
methodsWe prepared polyclonal anti-survivin serum to establish a survivin index for stained sections, using an immunohistochemical procedure, according to the method used for scoring MIB-1 index, and then stained 29 paraffin-embedded sections from surgical specimens of 29 patients who were classified into three grades of World Health Organization with the mean age of low grade astocytoma (grade II) being 34.7; anaplastic astrocytoma (grade III), 48.8; and glioblastoma multiform (grade IV), 58.4.
resultsOn staining with the anti-survivin antiserum, all specimens contained positive cells, but the survivin index was heterogeneous among grades. The mean percentage of immunoreactive cells in each specimen was 70.0 (SD 18.2) in grade II, 81.3 (16.5) in grade III, and 85.0 (13.6) in grade IV. Then we compared the survivin index to the MIB-1 index and found that in low-grade gliomas (grade II and III), the difference in survival times between the high and low survivin indexes was significant (P=0.007), whereas that between the high and low MIB-1 indexes was not significant (P=0.092). ONCLUSION: Survivin is more sensitive marker than MIB-1 for the evaluation of low-grade gliomas in that it helps to predict patient survival. Much larger glioma patient series are needed to validate the findings of our limited study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.